Physician profile
Lihong Wei
NPI 1861574576
$4,630.86
in general payments reported to CMS, 2019-2025
27 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,292 · 2020: $161 · 2021: $283 · 2022: $390 · 2023: $271 · 2024: $125 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $484 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $484.19 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $352.06 | 2019-2023 | Tecvayli, Darzalex, Rybrevant |
| Gilead Sciences, INC. | $330.92 | 2019-2022 | |
| Pfizer INC. | $325.08 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $303.67 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $265.00 | 2021-2022 | |
| Genentech USA, INC. | $262.87 | 2019 | |
| Incyte Corporation | $250.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.29 | 2019 | |
| Exelixis INC. | $222.24 | 2019 | |
| Lilly USA, LLC | $219.87 | 2019-2025 | Kisunla |
| Astellas Pharma US INC | $191.70 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $176.58 | 2019-2020 | |
| Amgen INC. | $151.80 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $144.21 | 2019 | |
| Merck Sharp & Dohme LLC | $139.01 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $125.00 | 2021 | |
| Ibsa Pharma INC. | $125.00 | 2024 | Licart |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $116.36 | 2019 | |
| Celgene Corporation | $112.08 | 2019 | |
| Seagen INC. | $111.00 | 2019 | |
| Tesaro, INC. | $108.85 | 2019 | |
| Novartis Pharmaceuticals Corporation | $99.18 | 2019 | |
| Verastem, INC. | $55.28 | 2019 | |
| Puma Biotechnology, INC. | $34.38 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $22.43 | 2019 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lihong Wei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.